Your session is about to expire
← Back to Search
UPLYFT for Lymphoma
N/A
Recruiting
Led By Oreofe O Odejide, MD, PhD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Lymphoma Survivors Phase 1 and 2: In complete remission after first line of treatment
Lymphoma Survivors Phase 1 and 2: Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights
Study Summary
This trial is testing an intervention to help improve quality of life and reduce lymphoma-related worries for survivors.
Who is the study for?
This trial is for adults over 18 who have been treated for lymphoma and are in remission but still experience significant fear of cancer recurrence. They must be within 3 to 24 months post-treatment, have access to a computer, and not have other untreated major psychiatric disorders or concurrent malignancies.Check my eligibility
What is being tested?
UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) is being tested. It's an intervention designed to help lymphoma survivors improve their quality of life by providing information on survivorship and tools to manage worries about the disease returning.See study design
What are the potential side effects?
Since UPLYFT involves informational support rather than medication, traditional side effects like those seen with drugs aren't expected. However, discussing fears related to cancer can potentially cause emotional discomfort.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am in complete remission from lymphoma after my first treatment.
Select...
I was diagnosed with a type of lymphoma.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Feasibility: Data Collection Completion Rate
Feasibility: Enrollment Rate
Feasibility: Program Session Completion Rate
Secondary outcome measures
Acceptability: Disenrollment Rate
Acceptability: Satisfaction Rate
Preliminary efficacy: Anxiety Change
+4 moreTrial Design
3Treatment groups
Experimental Treatment
Group I: UPLYFT PilotExperimental Treatment1 Intervention
Lymphoma survivors will participate in the phase 1 finalized, six session UPLYFT program.
Participants will be randomized 1:1 to either UPLYFT or usual care.
Group II: Lymphoma Survivors Field TestExperimental Treatment1 Intervention
A six person group of lymphoma survivors will participate in a six session UPLYFT program field test to provide feedback for the development of the UPLYFT program.
Group III: Clinicians InterviewsExperimental Treatment1 Intervention
Lymphoma and mental health clinicians will participate in 1x in-depth qualitative interview to provide feedback for the development of the UPLYFT program.
Find a Location
Who is running the clinical trial?
Dana-Farber Cancer InstituteLead Sponsor
1,079 Previous Clinical Trials
340,906 Total Patients Enrolled
59 Trials studying Lymphoma
2,312 Patients Enrolled for Lymphoma
American Society of HematologyOTHER
12 Previous Clinical Trials
20,916 Total Patients Enrolled
Oreofe O Odejide, MD, PhDPrincipal InvestigatorOreofe_Odejide@dfci.harvard.edu
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I finished my first lymphoma treatment between 3 and 24 months ago.I do not have untreated mental health conditions like psychosis, bipolar, or borderline personality disorder.I am in complete remission from lymphoma after my first treatment.I am a clinician treating lymphoma patients or a mental health professional caring for cancer patients.I do not have untreated mental health conditions like psychosis, bipolar, or borderline personality disorder.I have another type of cancer besides lymphoma.I am 18 years old or older and a lymphoma survivor.I am under 18 and a lymphoma survivor.I am under 18 years old and a lymphoma survivor.I was diagnosed with a type of lymphoma.I am an adult.I have lymphoma and another type of cancer at the same time.
Research Study Groups:
This trial has the following groups:- Group 1: Clinicians Interviews
- Group 2: UPLYFT Pilot
- Group 3: Lymphoma Survivors Field Test
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many participants are partaking in this experiment?
"Affirmative. According to clinicaltrials.gov, this experiment is actively recruiting patients with a posted date of February 8th 2022 and an amended posting on March 14th 2022. The study seeks 74 participants at one medical centre."
Answered by AI
What is the ultimate intent of this clinical inquiry?
"This clinical trial will assess the feasibility of program session completion rate over a 6 month period. Secondary parameters such as pre-intervention to post-intervention changes in anxiety (as measured by Hospital and Anxiety Scale) and psychological inflexibility (as assessed via Acceptance and Action Questionnaire-II) are also being evaluated, with an acceptability threshold set at ≤ 10% disenrollment rate."
Answered by AI
Is enrollment currently open for this research study?
"This trial, which was initially listed on February 8th 2022, is still open for patient recruitment. Accordingly, it has been updated as recently as March 14th 2022."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger